Locally limited inhibition of bone resorption and orthodontic relapse by recombinant osteoprotegerin protein by Schneider, D. A. et al.
ORIGINAL ARTICLE
D. A. Schneider
S. M. Smith
C. Campbell
T. Hayami
S. Kapila
N. E. Hatch
Locally limited inhibition of bone
resorption and orthodontic relapse
by recombinant osteoprotegerin
protein
Authors' afﬁliations:
D. A. Schneider, S. M. Smith, C. Campbell,
T. Hayami, S. Kapila, N. E. Hatch,
Department of Orthodontics and Pediatric
Dentistry, School of Dentistry, University
of Michigan, Ann Arbor, MI, USA
Correspondence to:
Nan E. Hatch
Department of Orthodontics and
Pediatric Dentistry
School of Dentistry
University of Michigan
1011 N University Avenue
Ann Arbor
MI, USA
E-mail: nhatch@umich.edu
Schneider D. A., Smith S. M., Campbell C., Hayami T., Kapila S., Hatch
N. E. Locally limited inhibition of bone resorption and orthodontic relapse
by recombinant osteoprotegerin protein
Orthod Craniofac Res 2015; 18(Suppl.1): 187–195. © 2015 John Wiley &
Sons A/S. Published by John Wiley & Sons Ltd
Structured Abstract
Objectives – To determine minimal dose levels required for local inhibition
of orthodontic relapse by recombinant OPG protein (OPG-Fc), while also
determining effects of injected OPG-Fc on alveolar bone and long bone.
Setting and Sample Population – The Department of Orthodontics and
Pediatric Dentistry at the University of Michigan. Eighteen male Sprague
Dawley rats.
Materials & Methods – Maxillary molars were moved with nickel–titanium
springs and then allowed to relapse in Sprague Dawley rats. Upon appli-
ance removal, animals were injected with a single dose of 1.0 mg/kg
OPG-Fc, 0.1 mg/kg OPG-Fc, or phosphate-buffered saline (vehicle) just
distal to the molar teeth. Tooth movement measurements were made from
stone casts, which were scanned and digitally measured. Alveolar tissues
were examined by histology. Micro-computed tomography was used to
quantify changes in alveolar and femur bone.
Results – Local injection of OPG-Fc inhibited molar but not incisor
relapse, when compared to vehicle-injected animals. No significant differ-
ences in alveolar or femur bone were seen between the three treatment
groups after 24 days of relapse.
Conclusions – Our results demonstrate that a single local injection of OPG-Fc
effectively inhibits orthodontic relapse, with minimal systemic bone metabolic
effects. Our results also show that a single injection of OPG-Fc will influence
tooth movement only in teeth close to the injection site. These findings indicate
that OPG-Fc has potential as a safe and effective pharmacological means to
locally control osteoclasts, for uses such as maintaining anchorage during
orthodontic tooth movement and preventing orthodontic relapse in humans.
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Introduction
Osteoclastogenesis is mediated by the ratio of
nuclear factor kappa B ligand (RANKL) to osteo-
protegerin (OPG), and inhibitors of RANKL can
inhibit bone resorptive activity (1). In humans,
injection with OPG-Fc or a monoclonal antibody
to RANKL leads to diminished serum markers of
bone resorption (2, 3), reduced fracture inci-
dence, and increased bone mineral density in
post-menopausal women (4, 5). In vivo evidence
also supports a role for RANKL and OPG in con-
trol of mechanically induced bone resorption
(6). Together, these studies demonstrate that
inhibitors of RANKL can be used to systemically
reduce bone resorption induced by biologic or
mechanical perturbations of bone.
Local control of osteoclasts through limited
delivery of RANKL inhibitors would be useful for
situations in which inhibition of bone resorption
is desirable only at specified locations. Ortho-
dontic tooth movement serves as a well-utilized
in vivo model of mechanically induced, local
bone modeling activity that is responsive to bio-
logic agents (7–9). That orthodontic tooth move-
ment is mediated by RANKL and OPG is
evidenced by previous findings showing that
compressive orthodontic forces increase RANKL
expression (10), and that manipulation of
RANKL or OPG levels by gene delivery can alter
the rate of orthodontic tooth movement (11, 12).
Similarly, we previously showed that injection
with OPG-Fc inhibits orthodontic tooth move-
ment (13). As a proof of concept study, high and
frequent doses were used and no attempt was
made to limit affects to local tissues. Corre-
spondingly, the results showed that the injected
OPG-Fc entered the systemic circulation in
amounts sufficient to influence osteoclasts dis-
tant from the site of injection.
Because orthodontic relapse involves tooth
movement through bone, it is also a bone model-
ing and remodeling process that requires osteo-
clast activity. We previously investigated OPG-Fc
as a potential mediator of orthodontic relapse.
Using multiple high doses of locally delivered
OPG-Fc, we found a robust inhibition of post-
orthodontic relapse (14). However, at this dose
and frequency, the OPG-Fc entered the systemic
circulation and had effects at sites distant from
the tooth being stabilized. From a clinical per-
spective, local inhibition of osteoclast activity
could allow for enhanced control of individual
teeth during orthodontic treatment and for spa-
tially restricted effects in the prevention of relapse
after orthodontic treatment. However, unless
appropriate doses or technologies can be vali-
dated for localizing the control of bone resorption
by RANKL inhibitors, the use of these agents for
this purpose is not likely to be realized. To date,
no studies have been performed to modulate the
local regulation of bone turnover by RANKL inhi-
bition. In this study, we utilized a rodent model of
orthodontic relapse to determine whether a single
injection of OPG-Fc will inhibit local alveolar
bone resorption and orthodontic relapse, while
having minimal effects on bones distant from the
site of injection.
Materials and methods
Animals and procedures
Orthodontic appliances were placed in eighteen
male Sprague Dawley rats that were randomly
assigned to three treatment groups of six animals
each. One volumetrically equivalent bolus of
1.0 mg/kg OPG-Fc (rat recombinant osteoproteg-
erin; Amgen, Inc., Thousand Oaks, CA, USA),
0.1 mg/kg OPG-Fc, or phosphate-buffered saline
(PBS) vehicle was injected immediately prior to
appliance removal, into the palatal mucosa just
distal to the maxillary first molars. Six animals
served as pre-tooth movement controls. An addi-
tional six animals that received orthodontic appli-
ances but no injections served as post-tooth
movement controls. All procedures were per-
formed in accordance with the University of Mich-
igan’s Committee on Use and Care of Animals.
Orthodontic appliance for tooth movement and relapse
Orthodontic forces were applied using a previously
established rodent model of tooth movement and
relapse (7, 14). During the tooth movement phase,
maxillary first molars were moved mesially, with
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nickel–titanium springs calibrated to provide 50
cN of force that were ligated from the molar to the
ipsilateral incisor tooth. Appliances were removed
after 28 days, and the teeth were allowed to
relapse for 24 days. Tooth movement was
measured at specific intervals during the tooth
movement and relapse phases of the experiment.
Measurements of orthodontic tooth movement and relapse
Tooth movement was measured as previously
described (14). Briefly, stone models made from
polyvinylsiloxane impressions were scanned at
1200 dpi and magnified 3009 and measured
using commercial software (Adobe Photoshop
CS6; Adobe Systems Inc. San Jose, CA, USA). The
amounts of molar and incisor relapse were calcu-
lated as the difference between the post-relapse
measurement and the post-tooth movement
measurement, as well as a percent of initial tooth
movement that accounted for differences in ini-
tial tooth movement between individual animals.
The intra-examiner and interexaminer errors for
tooth movement measurements were assessed by
two repeat measurements of first molar mesial
movement taken on 87 teeth, 2 weeks apart. A
Pearson’s correlation coefficient analysis demon-
strated very high intra-examiner (r = 0.99;
p < 0.0001) and interexaminer (r = 0.98;
p < 0.0001) reliability.
Histological analysis
Block biopsies of hemi-maxillae were fixed,
decalcified, and embedded in paraffin. Axial sec-
tions containing the first molar tooth roots were
obtained. Sections were stained with hematoxy-
lin and eosin for descriptive histology. Sections
were stained for tartrate-resistant acid phospha-
tase (TRAP-5b) for osteoclast identification using
commercially available reagents and following
the manufacturer’s protocol (Biocare Medical,
Concord, CA, USA).
Micro-computed tomography
Hemi-maxillae and femurs were harvested, fixed
in 10% formalin and transferred to ethanol.
Samples were embedded in agarose and scanned
using a micro-computed tomography system
(lCT100 Scanco Medical, Bassersdorf, Switzer-
land) at voxel size 18 lm3, 70 kVp, 114 lA. Scans
were calibrated to the manufacturer’s hydroxy-
apatite phantom. Analyses were conducted using
commercial software (Scanco Medical, Br€uttisel-
len, Switzerlandand) and are reported in accor-
dance with the recommendations of Bouxsein
et al. (15). Alveolar bone was analyzed in the
maxillary first molar furcation region according
to a previously established protocol (16),
because this bone undergoes modeling and
remodeling during and after orthodontic tooth
movement. Long bone analysis was performed
at the distal metaphysis of the femur.
Statistical analysis
Each animal was treated as a unit, and bilateral
measures were averaged to give a single measure
for each animal at each time point. Descriptive
statistics were calculated for each parameter for
all groups. A repeated measures analysis of vari-
ance (ANOVA) was performed at each time point
to compare tooth movement and relapse data
between groups and over time within a group,
using statistical software (SPSS version 20; SPSS
Inc., Chicago, IL, USA). Tukey’s post hoc tests
were performed to establish pairwise differences.
Results
Animal status
The animals tolerated the experimental proce-
dures well, with no discernible effect on overall
health. There were no significant differences in
weight gain between the treatment groups at
any time point during the study.
Orthodontic tooth movement and relapse movement
The amount of tooth movement achieved at the
time of appliance removal was similar in the
three groups of injected animals (0.61  0.25 mm
for vehicle control, 0.73  0.18 mm for 0.1 mg/kg
OPG-Fc and 0.74  0.33 mm for 1 mg/kg OPG-
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Fc). Representative micro-CT isosurface images
of pre-tooth movement, post-tooth movement
and post-relapse PBS, and OPG-Fc-injected ani-
mals are depicted in Fig. 1A. During the relapse
phase, the 0.1 mg/kg OPG-Fc-injected animals
showed significantly less linear (Fig. 1B) and per-
cent molar (Fig. 1C) relapse than the control ani-
mals at days 12, 18, and 24 days after appliance
removal. The 1.0 mg/kg OPG-Fc-injected animals
had significantly less linear and percent molar
relapse than the vehicle-injected animals at all
time points following appliance removal.
When comparing intragroup changes in molar
relapse over time, all of the treatment groups
showed significant distal molar relapse move-
ment from day zero to day three after appliance
removal. This result is expected because upon
appliance removal the tooth undergoes a
rebound shift within the tooth socket that does
not require osteoclast activity (17). Importantly,
whereas the vehicle-injected animals continued
to exhibit significant molar relapse movement
beyond this initial period, the OPG-Fc-injected
animals did not. Therefore, these results demon-
strate that OPG-Fc effectively inhibited molar
relapse beyond the original constraints of the
tooth socket.
To establish whether or not the effects OPG-Fc
were localized to the molars and did not affect
teeth distant from the site of injection, we also
A
DC
B
Fig. 1. A single local injection of OPG-Fc locally inhibits post-orthodontic molar relapse. (A) Sagittal micro-CT isosurface images
of representative pre-tooth movement, post-tooth movement, and vehicle, low-dose, and high-dose OPG-Fc-injected animals
after 24 days of relapse post-appliance removal are shown. Note the difference in interdental distance visible between the first
and second molar teeth in pre-tooth vs. post-tooth movement and in vehicle vs. OPG-Fc-injected animals. Red arrows indicate
the direction of molar distal relapse following appliance removal. (B) Incisor distal movement (0–28 days) and incisor mesial
relapse movement (29–52 days) of vehicle, 0.1 mg/kg OPG-Fc and 1.0 mg/kg OPG-Fc-injected animals are shown. Results are
expressed as the mean  SEM. All three groups achieved similar magnitudes of incisor movement after 28 days of orthodontic
force, and significant incisor movement after 28 days was found for all three groups (p < 0.001, pre-tooth movement vs. post-
tooth movement). Significant incisor relapse movement after 24 days was also found for all three groups (p < 0.001, post-relapse
vs. post-tooth movement). No significant differences between any of the three groups were found at any time point after appli-
ance removal, indicating that the injected OPG-Fc did not inhibit incisor relapse. (C) Linear maxillary first molar distal relapse
movements after appliance removal are shown for the vehicle, 0.1 mg/kg and 1.0 mg/kg injected animals. Results are expressed
as the mean  SEM. *p < 0.05 between the indicated group and vehicle-injected animals. (D) Molar distal relapse is presented as
a percentage of initial mesial molar movement to account for differences in initial tooth movement between individual animals.
Results are expressed as the mean  SEM. *p < 0.05 between the indicated group and vehicle-injected animals.
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measured incisor orthodontic tooth movement
and relapse (Fig. 1D). The vehicle-injected,
0.1 mg/kg OPG-Fc-injected and 1.0 mg/kg OPG-
Fc-injected animals exhibited very similar incisor
relapse movement following appliance removal.
This finding, combined with the fact that incisor
relapse reached close to 95% for all of the treat-
ment groups, indicates that the injected OPG-Fc
did not inhibit relapse of teeth that were more
distant from the site of injection.
Descriptive histology
Alveolar tissue sections from immediate post-
tooth movement animals showed a widened
PDL space with a loss of supporting alveolar
bone and isolated areas of root resorption in
representative samples, as compared to the pre-
tooth movement samples (Fig. 2A–C). These
findings are consistent with the known process
of orthodontic tooth movement (7, 18). Alveolar
tissue sections from post-tooth movement ani-
mals also exhibited a higher presence of Trap5b-
stained osteoclasts as compared to sections from
pre-tooth movement animals (Fig. 2D). Follow-
ing 24 days of relapse after appliance removal,
tissue sections from animals of all three injec-
tion groups demonstrated a return to near base-
line presentation, with fewer osteoclasts and an
increase in alveolar bony support. Trap5b stain-
ing was diminished in all relapse groups as com-
pared to that seen in post-tooth movement
animals. OPG-Fc-injected animals did not show
reduced levels of Trap5b staining as compared
to vehicle-injected animals after 24 days of
relapse.
Alveolar bone micro-computed tomography
To determine whether a single dose of OPG-Fc
alters bone near the injection site, we analyzed
alveolar bone investing the first molar tooth
roots (Table 1). Multiple measurements showed
trends toward decreased alveolar bone quantity
and quality in the post-tooth movement animals
as compared to the pre-tooth movement ani-
mals. Multiple measurements showed signifi-
cantly increased bone quantity and quality after
the relapse period in vehicle-injected animals,
when compared to the values for the post-tooth
movement animals. Of greatest relevance to this
study, no significant differences were seen
between the three treatment groups for any of
the measurements at the end of the relapse
period.
Femur micro-computed tomography
Measures of femur bone in the three treatment
groups at the end of the relapse period were
similar, and no significant differences between
any of the three groups for any of the measured
bone parameters were evident (Table 2).
Discussion
Our group has focused upon the use of OPG-Fc
for regulating orthodontic tooth movement and
for mitigating relapse after tooth movement (14),
because OPG-Fc was previously shown to be
both safe and efficacious for inhibiting bone
resorption in humans (2). Our previous studies
showed that while serial injection of OPG-Fc can
significantly inhibit orthodontic tooth movement
and relapse after tooth movement, it also intro-
duces OPG-Fc into the general circulation and
therefore has the capacity to influence bone sys-
temically (13, 14). In this study, we sought to
determine whether a single local injection of
OPG-Fc could inhibit orthodontic relapse with-
out leading to systemic effects upon bone.
Histologic staining of the alveolar bone tissue
showed that Trap5b staining for osteoclasts was
not reduced in OPG-Fc injected, as compared to
vehicle-injected animals 24 days after the injec-
tion. This staining pattern suggests that the
locally administered OPG-Fc was no longer
active after 24 days of relapse. This finding is
not surprising given the relatively short half-life
of OPG-Fc of several days (19). In this study, we
also found no significant differences in micro-
CT-based parameters of local alveolar bone
quality between any of the three injection
groups at the end of the 24 day relapse period,
indicating that a single local injection of OPG-Fc
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does not have long-term effects on alveolar bone.
It is possible that the injected OPG-Fc had signifi-
cant short-term effects on alveolar bone that were
lost in the long term, due to loss of drug activity
over time. In future studies, it will be important to
measure changes in alveolar bone quality at ear-
lier time points after appliance removal to estab-
lish more accurately the timing of the biologic
processes of bone remodeling and maturation
after cessation of tooth movement, and to deter-
mine the best therapeutic window for pharma-
ceutical prevention of orthodontic relapse.
The effects of injected OPG-Fc remained local,
as is supported by the findings that both OPG-
Fc and vehicle-injected animals exhibited up to
95% relapse of incisor tooth movement and that
no differences in incisor relapse were noted
between the three treatment groups. This finding
is in stark contrast to our previous results, which
showed that multiple injections of OPG-Fc had
significant inhibitory effects upon incisor relapse
(14). Results presented here demonstrate that a
single, locally injected dose of OPG-Fc can be
expected to have effects that are limited to the
area surrounding the injection site. From a clini-
cal viewpoint, these findings suggest that a sin-
gle injection of OPG-Fc could potentially be
utilized to enhance orthodontic anchorage
locally, without inhibiting overall tooth move-
ment. The findings may also suggest that the
retentive effect of a low-dose OPG-Fc injection
is limited to teeth immediately surrounding the
A
B
C
D
Fig. 2. Alveolar bone changes due to orthodontic tooth movement and relapse after movement. Representative photomicrographs
of hematoxylin-and-eosin-stained sections of the alveolar bone investing the first molar roots before tooth movement, after tooth
movement, and after relapse are shown. Arrows indicate the mesial direction of orthodontic tooth movement. Box outlines in A
indicate areas shown in B and C. (A) 49 magnification of alveolar bone investing the first molar roots showing all five roots of
the maxillary molar. (B) 109 magnification showing alveolar bone surrounding the disto-palatal molar root outlined in A. (C) 109
magnification showing alveolar bone between the mesial molar root and the palatal molar root, as outlined in A. (D) Representa-
tive photomicrographs of alveolar bone sections investing the first molar roots stained with Trap5b for osteoclasts and osteoclast
precursors, before tooth movement, after tooth movement, and after relapse are shown. Note that Trap5b staining is increased in
the local alveolar bone after 28 days of tooth movement and is then decreased 24 days after appliance removal. Also note Trap5b
staining is not reduced in 0.1 mg/kg or 1.0 mg/kg injected animals to a greater extent than vehicle-injected animals. Box outlines
in A indicate areas shown in B. 49 magnification of alveolar bone investing the first molar roots showing all five roots of the
maxillary molar.
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injection site. On a more global scale, these
results demonstrate that exogenous inhibitors of
RANKL have potential for local control of osteo-
clast activity in vivo. While treatment with the
inhibitory monoclonal antibody to RANKL (De-
nosumab; Amgen, Inc.) may be more beneficial
for systemic bone effects in osteoporotic patients
due to its longer half-life of approximately
28 days, treatment with OPG-Fc may be more
appropriate for achieving more limited and local
effects, in part due to its shorter half-life of 5–
7 days (3, 19).
Results of this study demonstrate that a single
injection of OPG-Fc upon appliance removal sig-
nificantly inhibits relapse after orthodontic tooth
movement and that a single injection of 1.0 mg/
kg OPG-Fc inhibits relapse to a greater extent
than an injection of 0.1 mg/kg OPG-Fc. Notably,
relapse in the 1.0 mg/kg OPG-Fc-injected animals
remained at approximately 20% of the initial
tooth movement at 24 days after appliance
removal. This striking inhibition of relapse is sim-
ilar to that which was reported for multiple injec-
tions/week of OPG-Fc (14) and indicates that a
single injection of OPG-Fc is as efficacious for
preventing relapse as multiple injections of OPG-
Fc for at least 24 days after appliance removal.
Future studies are required to determine the
extent of longevity of this effect. Future studies
are also required to determine whether inhibition
of orthodontic relapse requires sustained inhibi-
tion of osteoclasts, or if transient inhibition of os-
teoclasts during a critical time-limited period
after orthodontic appliance removal is sufficient.
Limitations of this study include the fact that
the period post-appliance removal was limited to
Table 1. Local alveolar bone volume, density, and structural parameters
Pre-tooth
movement
Post-tooth
movement
Control
post-relapse
0.1 mg/kg
OPG-Fc
post-relapse
1.0 mg/kg
OPG-Fc
post-relapse
Bone volume (mm3) 2.8  0.3 2.6  0.9 3.7  0.6a,b 3.4  0.3a,b 3.8  0.8a,b
Bone volume fraction 0.81  0.03 0.77  0.07 0.91  0.04a,b 0.91  0.02a,b 0.91  0.03a,b
Bone mineral density (mg/cc) 831  23 785  65 906  29a,b 892  35a,b 924  33a,b
Tissue mineral density (mg/cc) 1022  23 986  42 1004  22 988  34 1027  17
Trabecular number 4.4  0.3 4.6  0.6 4.0  0.6 4.4  0.4 4.0  0.5
Trabecular thickness 0.29  0.02 0.27  0.04 0.38  0.07a,b 0.33  0.04a,b 0.37  0.05a,b
Trabecular spacing 0.18  0.03 0.17  0.04 0.09  0.01a,b 0.08  0.02a,b 0.09  0.03a,b
Connectivity density 15.1  4.3 33.5  15.8a 10.2  6.6a,b 11.4  7.5a,b 13.0  9.4a,b
ap < 0.05 vs. pre-tooth movement.
bp < 0.05 vs. post-tooth movement.
Table 2. Femur bone volume, density, and structural parameters
Control post-relapse 0.1 mg/kg OPG-Fc post-relapse 1.0 mg/kg OPG-Fc post-relapse
Bone volume (mm3) 9.9  2.0 8.8  2.5 10.7  2.4
Bone volume fraction 0.60  0.09 0.52  0.12 0.61  0.08
Bone mineral density (mg/cc) 392  81 380  78 429  70
Tissue mineral density (mg/cc) 708  17 717  37 701  71
Trabecular number 5.3  0.6 4.7  0.5 5.6  0.3
Trabecular thickness 0.14  0.01 0.14  0.02 0.15  0.04
Trabecular spacing 0.15  0.03 0.19  0.05 0.14  0.02
Connectivity density 74.4  6.2 75.2  16.3 80.3  9.8
No signiﬁcant differences between the three relapse groups were found.
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28 days of relapse. Future studies are required to
establish how long a single local injection of OPG-
Fc can inhibit relapsed tooth movement. This
study also did not include analysis of tissues at
multiple time points of relapse. Additional studies
investigating bone, PDL, and tooth changes over
time during relapse could further illuminate bio-
logic processes underlying tooth movement post-
orthodontic treatment. Such knowledge would
guide future studies inhibiting specific aspects of
these processes. This investigation was also per-
formed in rodents, as opposed to larger mam-
mals, primates, or humans. It remains unknown if
a local injection of OPG-Fc will inhibit orthodon-
tic relapse in humans.
A primary goal of this study was to determine
the minimum effective dose of OPG-Fc for
achieving maximal local clinical efficacy while
minimizing potential systemic side effects.
Toward this goal, we utilized micro-CT to assess
changes in long bone quality. Measures of femur
bone were similar after relapse, for all of the
three injection groups. While further studies are
required to definitively establish both immediate
and long-term effects of locally delivered OPG-
Fc on long bones, our results indicate that a sin-
gle injection of low-dose OPG-Fc to prevent
relapse will likely have minimal long-term effects
on long bone volume, density, and structure.
Conclusions
A single local injection of OPG-Fc can inhibit
orthodontic relapse in rodents, with minimal
systemic bone metabolic effects. A single injec-
tion of OPG-Fc will influence tooth movement
only in teeth close to the injection site. These
findings indicate that OPG-Fc has potential as
a safe and effective pharmacological means to
control osteoclasts locally, for uses such as
maintaining anchorage during orthodontic
tooth movement and preventing orthodontic
relapse. Future studies are required to establish
efficacy in humans.
Clinical relevance
Post-treatment relapse is a significant challenge
in clinical orthodontics. When delivered at doses
sufficient to inhibit osteoclasts systemically,
recombinant OPG protein (OPG-Fc) was previ-
ously shown to inhibit orthodontic tooth move-
ment and relapse. While systemic inhibition of
osteoclast activity is beneficial for systemic dis-
orders of bone such as osteoporosis, local con-
trol of osteoclasts would be useful for situations
in which inhibition of bone resorption is desir-
able only at specified locations. The purpose of
this study was to determine the minimum effec-
tive dose of OPG-Fc for locally preventing ortho-
dontic relapse, while minimizing potential
systemic side effects.
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